NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
ALTOPREV (lovastatin) by Merck & Co. is clinical pharmacology the involvement of low-density lipoprotein cholesterol (ldl-c) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments. First approved in 2002.
Drug data last refreshed 15h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTOPREV (lovastatin) is an oral extended-release HMG-CoA reductase inhibitor (statin) that reduces LDL cholesterol by inhibiting cholesterol biosynthesis and upregulating LDL receptors. It is indicated for patients with elevated cholesterol levels at risk for coronary heart disease. The drug works by blocking the conversion of HMG-CoA to mevalonate, an early step in cholesterol synthesis.
$0.762MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D penetration (508 claims, $762K spend in 2023), indicating a mature, commoditized franchise with limited team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY The involvement of low-density lipoprotein cholesterol (LDL-C) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments. Epidemiological and clinical studies have established that high LDL-C and low high-density…
Worked on ALTOPREV at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.